Breaking News

Hong Kong-based Rainbow Genomics will provide exome sequencing while UCLA will interpret the data and deliver a clinical report.

Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.

The firm saw modest growth in both its life science and diagnostics divisions and increased its guidance for the year.

Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.

The partners have agreed to codevelop targeted sequencing kits based on single-molecule molecular inversion probes.

The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.

The company said it will use the proceeds for technology development and to expand its global footprint, among other things.

Based on genome data for 3,010 Asian rice accessions, researchers retraced the domestication history and diversity of Xian/Indica and Geng/Japonica rice.

Based on the strong first quarter results, the company raised its revenue and earnings guidance for the year.

Researchers at the annual Association of Biomolecular Resource Facilities meeting said they are joining single-cell sequencing to other single-cell analyses.

The company's $782 million in revenues were driven by both its sequencing and microarray businesses.

At the Association of Biomolecular Research Facilities annual meeting this week, the ABRF Genomics Research Group presented results from its comparison of single-cell RNA sequencing platforms.

By sequencing and characterizing the genome of Artemisia annua, researchers uncovered gene expansions and regulatory features linked to artemisinin production.

The fund has received an initial $30 million commitment from Aspire and health system Penn Medicine Lancaster General Health.

Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.

In analyses of multiple traits and diseases, investigators uncovered loss-of-function or truncating changes with apparent protective effects.

The firm said total test volumes rose 55 percent during the quarter, and test volumes for its SelectMDx liquid biopsy test nearly tripled in Europe.

Organic revenues were up 2 percent, as the company saw solid demand among its pharma customers but a decline in sales of its mass spectrometry instruments.

The company submitted the platform and gastrointestinal panel to the US Food and Drug Administration for clearance earlier this year.

The lawsuits were filed after the HHS OIG subpoenaed the firm as part of an investigation into how it billed Medicare and Medicaid for the myRisk test.

Data from almost 19,500 individuals did not show clear ties between a heterozygous mutation in the HBB hemoglobin beta gene and ischemic stroke risk.

NuProbe said it will use the funding to expand its staff and to continue development of its toehold hybridization probe technology.

The exclusive deal includes sales and marketing of a rapid thermal cycler as well as consumable microplates and pipette tips. 

Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.

Last week, GenomeWeb's readers were most interested in the results from several highly anticipated immuno-oncology clinical trials.

Pages

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.